We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
-5.86%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.62B
AUM Growth
-$2.78B
(-33%)
Cap. Flow
-$2.47B
Cap. Flow
% of AUM
-43.88%
Top 10 Holdings %
Top 10 Hldgs %
56.27%
Holding
465
New
101
Increased
59
Reduced
84
Closed
204
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$44.1M |
| 2 |
Harmony Biosciences
HRMY
|
+$36.9M |
| 3 |
Travere Therapeutics
TVTX
|
+$33.9M |
| 4 |
MDLN
Medline Inc
MDLN
|
+$22.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$20.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kenvue
KVUE
|
+$70.6M |
| 2 |
Immunovant
IMVT
|
+$56.5M |
| 3 |
Dentsply Sirona
XRAY
|
+$53.6M |
| 4 |
GE HealthCare
GEHC
|
+$53.1M |
| 5 |
PTC Therapeutics
PTCT
|
+$51.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.27% |
| 2 | Technology | 7.29% |
| 3 | Consumer Discretionary | 4.25% |
| 4 | Communication Services | 1.58% |
| 5 | Consumer Staples | 1.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
PennyMac Financial
PFSI
$4.36B
| $202K | ﹤0.01% |
+2,306
| New | +$248K |
|
|
AKTX
227
Akari Therapeutics
AKTX
$18.7M
| $200K | ﹤0.01% |
38,922
-29,177
| -43% | -$273K |
|
|
IVF
228
INVO Fertility Inc
IVF
$1.86M
| $195K | ﹤0.01% |
71,866
+30,337
| +73% | +$152K |
|
229
Virax Biolabs
VRAX
$3.09M
| $193K | ﹤0.01% |
+35,152
| New | +$216K |
|
230
Maris-Tech Ltd Warrants
MTEKW
$1.1M
| $190K | ﹤0.01% |
1,261,058
| – | – |
|
231
Bath & Body Works
BBWI
$4.13B
| $187K | ﹤0.01% |
+10,032
| New | +$217K |
|
232
Garrett Motion
GTX
$6.06B
| $184K | ﹤0.01% |
+10,146
| New | +$189K |
|
233
Zeta Global
ZETA
$5.28B
| $175K | ﹤0.01% |
10,997
-417,232
| -97% | -$7.72M |
|
|
USAR
234
USA Rare Earth Inc
USAR
$3.87B
| $156K | ﹤0.01% |
+10,322
| New | +$200K |
|
|
BIVIW
235
BioVie Inc Warrant
BIVIW
$157K
| $155K | ﹤0.01% |
500,000
| – | – |
|
236
BGC Group
BGC
$5.36B
| $152K | ﹤0.01% |
+15,532
| New | +$144K |
|
237
Rivian
RIVN
$25.7B
| $151K | ﹤0.01% |
+10,007
| New | +$160K |
|
238
Telus
TU
$15.9B
| $149K | ﹤0.01% |
+11,646
| New | +$158K |
|
|
BESS.WS
239
Bimergen Energy Corp Warrants
BESS.WS
| $134K | ﹤0.01% |
+187,500
| New | +$145K |
|
240
Caleres
CAL
$398M
| $125K | ﹤0.01% |
+11,847
| New | +$141K |
|
|
SFIX
241
Stitch Fix
SFIX
$522M
| $124K | ﹤0.01% |
+37,522
| New | +$153K |
|
242
First Watch Restaurant Group
FWRG
$766M
| $118K | ﹤0.01% |
+11,234
| New | +$162K |
|
|
ERNAW
243
Ernexa Therapeutics Warrants
ERNAW
$930K
| $112K | ﹤0.01% |
+4,000,000
| New | +$237K |
|
244
American Airlines Group
AAL
$10.1B
| $111K | ﹤0.01% |
10,335
-22,172
| -68% | -$294K |
|
245
PDS Biotechnology
PDSB
$40.1M
| $105K | ﹤0.01% |
173,605
-2,660,901
| -94% | -$2M |
|
246
Portillo's
PTLO
$324M
| $88.4K | ﹤0.01% |
+16,719
| New | +$91K |
|
247
Designer Brands
DBI
$288M
| $68.7K | ﹤0.01% |
+12,082
| New | +$81.2K |
|
248
The Honest Company
HNST
$426M
| $62.5K | ﹤0.01% |
+21,242
| New | +$54.6K |
|
|
BDRX
249
Biodexa Pharmaceuticals
BDRX
$1.6M
| $60.3K | ﹤0.01% |
19,504
-496
| -2% | -$3.49K |
|
250
Heartbeam Inc Warrant
BEATW
$83.6K
| $60K | ﹤0.01% |
500,000
| – | – |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Armistice Capital held 465 positions worth $5.62B, down 33% from $8.4B the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Armistice Capital withdrew a net $2.47B in Q1 2026, closing 204 positions and reducing 84 holdings. Its most notable exit was argenx, an estimated $48.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 33% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Armistice Capital opened a new position in UnitedHealth worth $40M.
- Armistice Capital's largest Q1 2026 buy was UnitedHealth: 148,000 shares worth $40M.
- Armistice Capital added most to Harmony Biosciences in Q1 2026, an estimated $36.9M increase.
- Armistice Capital's biggest Q1 2026 reduction was Kenvue, cutting an estimated $70.6M.
- Armistice Capital fully exited argenx in Q1 2026, selling an estimated $48.8M.
- Armistice Capital's ten largest holdings make up 56% of its $5.62B portfolio in Q1 2026.
- Armistice Capital opened 101 new positions and closed 204 in Q1 2026.
- Armistice Capital's portfolio value fell 33% quarter-over-quarter to $5.62B.
Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.